Put companies on watchlist
SynBiotic SE
ISIN: DE000A3E5A59
WKN: A3E5A5
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

SynBiotic SE · ISIN: DE000A3E5A59 · EQS - Company News (32 News)
Country: Germany · Primary market: Germany · EQS NID: 1495559
24 November 2022 10:13AM

SynBiotic SE attracts Canopy Growth founder Bruce Linton as Chairman of newly created Advisory Board


EQS-News: SynBiotic SE / Key word(s): Personnel
SynBiotic SE attracts Canopy Growth founder Bruce Linton as Chairman of newly created Advisory Board

24.11.2022 / 10:13 CET/CEST
The issuer is solely responsible for the content of this announcement.


SynBiotic SE attracts Canopy Growth founder Bruce Linton as Chairman of newly created Advisory Board

 

Munich, 24th November 2022:

 

SynBiotic SE, (SBX.DE) one of Germany’s leading cannabinoid companies, accelerates implementation of the operational platform to achieve market leadership in the upcoming national legalization of recreational cannabis by securing Bruce Linton to its team.

 

Mr. Linton is one of the most experienced and most successful cannabis entrepreneurs and investors globally and has been the driving force behind the creation of multiple global multi-billion dollar cannabis enterprises, several of them listed on NYSE, Nasdaq, TSX, TSX:V, CSE and ASX.

 

Most notably, Mr. Linton is the founder and former Chairman and CEO of the global cannabis company Canopy Growth Corporation, which, at the time of his departure, had a market valuation of approximately CAD 20 billion and more than 25% market share in the Canadian recreational market while also being a global top tier supplier. Canopy was the first North American supplier to the German medical cannabis market. Combining unparalleled expertise in the areas of both medical and recreational cannabis, Mr Linton is a powerful asset given SynBiotic’s expansion plans, which cover both segments.

 

Mr. Linton has been appointed as Chairman of SynBiotic’s newly created Advisory Board and has invested capital in the company’s most recent financing round. His investment plus options to buy further shares from existing shareholders will bring him to an ownership of approx. 5% in SynBiotic.

 

He will draw no fixed cash salary and will be remunerated based on share price performance and other operational milestones, giving him full alignment with shareholders.

 

Mr. Linton stated “I see enormous potential in the European market, particularly in Germany because of the recently announced legalization in Europe’s largest economy. I regard SynBiotic as best positioned to take full advantage of the legalization and become Europe’s dominant cannabis company. I am very much looking forward to being part of this success story and to working with the amazing team around founder Lars Müller.“

 

Lars Müller, CEO of SynBiotic SE, states: “The fact that we are working with Bruce Linton is a true accolade. With the forthcoming legalization of recreational cannabis in Germany, SynBiotic SE will benefit massively from the know-how of one of the global industry pioneers. His faith in SynBiotic SE is a great honor for me and shows us that we are on the right track with our vision."

 

 

 

About SynBiotic SE

 

SynBiotic SE is the largest listed group of companies in Europe in the hemp and cannabis sector and pursues a buy-&-build investment strategy focused across the European Union. The group of companies covers the entire supply chain from cultivation through production to retail - from field to shelf. A core business of the company is the research & development, production and marketing of cannabinoid and terpene-based solutions to address major societal problems such as pain, sleep deprivation and anxiety. In addition to the food supplement and cosmetics market, SynBiotic SE is also active in the medical sector, and will shortly also enter the recreational cannabis sector.

 



24.11.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: SynBiotic SE
Barer Str. 7
80333 München
Germany
E-mail: office@synbiotic.com
Internet: https://www.synbiotic.com/
ISIN: DE000A3E5A59
WKN: A3E5A5
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Munich, Tradegate Exchange
EQS News ID: 1495559

 
End of News EQS News Service

1495559  24.11.2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1495559&application_name=news&site_id=boersengefluester_html
Visual performance / price development - SynBiotic SE
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.